The University of Texas System

Other

The Uab Research Foundation (the University of Alabama at Birmingham)

Frolova, Elena

El-Hennawy, Adel Sayed

Elena Frolova

Ilya V Frolov

Scott C Weaver

Peter W Mason

Adel Sayed El-Hennawy

Peter C Mason

The present disclosure relates to a catheter lock solution which instills into the lumen of the catheter and helps to maintain catheter patency when the catheter is not used for treatment of a patient. In particular, the present invention and its embodiments relate to a use of sodium bicarbonate solution as a catheter lock solution.

Catheter lock solution

The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions.

Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

A Sodium Bicarbonate Catheter Lock Solution that prevents clot formation inside the catheter lumen and ensures patency of the catheter and also eliminates bleeding and other complications caused through the use of anticoagulants and other solutions as a catheter locking solution. Said lock solution may be used with or without other components such as antimicrobials/antibiotics and/or anti-coagulants/anti-clotting agents.

Lock solution for venous catheters using sodium bicarbonate

The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.

Methods and compositions for pseudoinfectious alphaviruses

The present invention discloses a replication-deficient pseudoinfective virus belonging to the Flaviviridae family that lack the capsid gene, where the replication-deficient pseudoinfective virus propagates only in cells expressing the capsid or capsid, prM and envelope protein of the flavivirus. The present also discloses the method of producing such viruses on a large scale and the use of these pseudoinfective viruses as vaccines for preventing diseases caused by infections of humans or animals by the viruses belonging to this family.

Pseudoinfectious flavivirus and uses thereof

The present invention provides alphavirus replicons and methods of their use in producing heterologous protein.

Methods and compositions for alphavirus replicons

The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, &#x2dc;35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, C30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of C, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of Cby its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.

Attenuation of encephalitogenic alphavirus and uses thereof

[object Object]

The present invention provides a Venezuelan equine encephalitis virus replicon RNA useful in the development of stable lines of mammalian, avian and insect cells in which these replicons will persistently replicate. Venezuelan equine encephalitis (VEE) virus replicons contain a number of unique adaptive mutations that make the replicons noncytopathic. The replicons remain resistant to IFN-&#x3b1;/&#x3b2;. Replicon replication leads to high-level production of heterologous proteins, which are encoded by the replicons' genome and are under the control of a viral subgenomic promoter. Also provided are methods of screening for inhibitory compounds of Venezuelan equine encephalitis virus replication and eastern equine encephalitis virus replication.

Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof

Large-scale packaging of alphavirus replicons is accomplished by co-transfecting host cells with three RNA molecules: (1) an alphavirus replicon comprising a sequence encoding a heterologous protein; (2) a helper RNA encoding a capsid protein and (3) a helper RNA encoding two alphavirus glycoproteins. The helper RNAs contain cis-acting elements that allow efficient replication of the helper RNAs and their packaging into viral particles as well as packaging of replicon genomes. These populations of viral particles can be propagated at high titers in cell culture by infecting cells at high multiplicity. Propagation of packaged replicons at an escalating scale is useful for large-scale production of recombinant proteins and/or vaccine.

Growing community of inventors

Birmingham, AL, United States of America

Elena Frolova